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Abstract:  Tumor  markers  are  substances,  usually  proteins,  produced  by  the  body  in 
response to cancer growth, or by the cancer tissue itself. They can be detected in blood, 
urine, or tissue samples, and the discovery and detection of tumor markers may provide 
earlier  diagnosis  of  cancer  and  improved  therapeutic  intervention.  Colorimetric 
immunoassays  for tumor marker detection have attracted considerable attention, due to 
their simplicity and high efficiency. The traditionally used colorimetric immunoassays for 
the detection of tumor markers are based on enzyme-linked immunosorbent assays, and the 
great achievement of nanotechnology has further opened opportunities for the development 
of such kind of immunoassays. This paper will summarize recent advances in the field of 
colorimetric  immunoassays  for detecting tumor markers, which is  aimed to  provide an 
overview in this field, as well as experimental guidance for the learner. 
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1. Introduction 
Cancer is a leading cause of death worldwide, causing about 13% of all human deaths in 2007 
(7.6 million), and deaths from cancer are projected to continue rising, with an estimated 12 million 
deaths projected for 2030. According to the World Health Organization, more than 30% of cancer 
deaths could be prevented if the cases were detected early and treated [1]. So, one key point of ultimate 
success for cancer treatment is the accurate diagnosis at the early stages.  
Traditional methods for the diagnosis of cancer are endoscopy, biopsy and cytology specimen tests, 
as well as imaging/radiology tests, such as X-ray, positron emission computed tomography-computer 
tomography (PET-CT) and magnetic resonance imaging (MRI) [2–5]. Unfortunately, these diagnostic 
methods are not very powerful for the diagnosis of cancer at early stages, and some of these methods 
are quite time-consuming, expensive; thus not available for to a large number of people [6]. Therefore, 
the development of simple and rapid strategies that are specific and reliable for the diagnosis of cancer 
at early stages is of utter importance. 
It  has  been known that cancer cells or other related non-tumor cells can release specific tumor 
markers, which are usually proteins, as tumors develop, into the circulation system in response to 
cancer growth. These tumor markers can be detected in blood, urine, or tissue samples, and the level of 
them  is  associated  with  the  stage  of  cancer  [7–10].  Alongside  the  development  of  proteomic 
technologies, lots of protein tumor markers have been discovered for many types of cancer (Table 1) 
[11–18]. Considering the high importance and potential application in the early diagnosis of cancer, 
detection  of  tumor  markers  has  received  more  and  more  attention  [19–23].  While  some  novel 
immunoassays  have  been  developed  [24–33], a  variety of techniques have been employed for the 
development of these assays. Table 2 summarizes some examples of immunoassays which have been 
developed  for  tumor  markers  analysis  [33–49].  Among  the  various  detection  techniques,  the 
colorimetric method, in which the event is disclosed through a visual color change in the reaction 
medium, has proven the most convenient [50,51]. Thus, remarkable progress has been made on the 
design of colorimetric sensing systems for tumor marker detection over the years. 
Table 1. Some tumor markers currently in use. 
Tumor Markers  Related Cancers  Usual Sample  Refs. 
AFP (Alpha-fetoprotein)  Liver, germ cell cancer of ovaries or testes  Blood  [11] 
CA 15-3 (Cancer antigen 15-3)  Breast  Blood  [7] 
CA-125 (Cancer antigen 125)  Ovarian  Blood  [12] 
CEA (Carcinoembryonic antigen)  Colorectal, breast, thyroid et al.  Blood  [13] 
Estrogen receptors  Breast  Tissue  [14] 
hCG (Human chorionic gonadotropin)  Testicular and trophoblastic disease  Blood, urine  [15] 
Her-2/neu  Breast  Tissue  [16] 
Progesterone receptors  Breast  Tissue  [14] 
PSA (Prostate specific antigen)  Prostate  Blood  [17,18] 
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Table 2. Examples of immunoassays for tumor markers analysis. 
Tumor 
markers 
Biosensor principle  Assay principle  Limit of 
detection 
Refs. 
PSA  Fluorescence  Fluorophore-based bio-barcode amplification method  30 nM  [33] 
PSA  Microcantilever  Microcantilever  2 nM  [34] 
PSA  Electrochemistry  Using gold nanoparticle film electrodes and multienzyme-particle 
amplification 
5 fM  [35] 
PSA  Electrochemistry  Carbon nanotube amplification strategies  40 fM  [36] 
PSA  Surface-Enhanced 
Raman Scattering  
Immunoassay based on Surface-Enhanced Raman Scattering and 
immunogold labels 
30 fM  [37] 
PSA  Colorimetry  Homogenous growth of gold nanocrystals  10 fM  [38] 
AFP  Fluorescence  Fluorescence quenching signal of gold nanoparticles  0.17 nM  [39] 
AFP  Mass spectrometry  Mass spectrometry signal amplification using small-molecule 
tagged gold microparticles 
1 nM  [40] 
AFP  Electrochemistry  Amperometric enzyme immunosensor based on gold nanoparticles 
and multi-walled carbon nanotube composite membranes 
0.6 pM  [41] 
AFP  Chemiluminescence  Multilayers enzyme-coated carbon nanotubes as label  0.1 pM  [42] 
AFP  Colorimetry  Cascade enzyme-linked immunosorbent assay  0.1 pM  [43] 
AFP  Colorimetry  DNAzyme functionalized nano-probes  1.4 pM  [44] 
CEA, 
AFP 
Colorimetry  Colorimetric multiplexed immunoassay based on gold nanoparticles  0.02 ng/mL; 
0.1 pM 
[45] 
CEA  Chemiluminescence  Flow-through multianalyte system with substrate zone-resolved 
technique 
0.6 ng/mL  [46] 
CEA  Electrochemistry  Layer-by-layer assembly of gold nanoparticles-multi-walled carbon 
nanotubes-thionine multilayer films 
0.01 ng/mL  [47] 
CEA  Surface-Enhanced 
Raman Scattering 
Surface-Enhanced Raman Scattering of hollow gold nanospheres  0.01 ng/mL  [48] 
CEA  Colorimetry  Enzyme-labeled gold nanoparticle probes  0.012 ng/mL  [49] 
Large  quantities  of  colorimetric  assays  for  detecting  tumor  markers  are  proposed  based  on 
enzyme-linked  immunosorbent  assay  (ELISA)  [52–59].  Conventional  ELISA-based  colorimetric 
immunoassays may confront a serious sensitivity problem however, so low concentrations of tumor 
markers cannot be identified at the early stages of cancer. Therefore, research efforts have been focused 
mainly on the development of new signal amplification methods in colorimetric immunoassays. For 
instance, by incorporation of an enzyme-cascading step into the ELISA system, Lee et al. have reported 
a novel cascading ELISA, yielding detection limits of between 100 fM and 10 pM for both Prostate 
specific antigen (PSA) and Alpha-fetoprotein (AFP) in human serum [43]. Meanwhile, the emergence 
of nanotechnology is opening new horizons for highly sensitive detection of tumor markers [6,60–62]. 
Due to their excellent properties, many kinds of nanomaterials have been employed in colorimetric 
assays for detecting tumor markers [63–65]. 
Among the nanomaterials employed for the colorimetric detection of tumor markers, Au-NPs are 
the most commonly used, due to their unique optical properties. Their optical properties are strongly 
dependent  on  not  only  the  size  but  also  aggregation  state  of  the  particles,  so  smaller  individual 
nanoparticles  appear  wine  red  while  larger  particles  or  aggregates of smaller particles  range  from Int. J. Mol. Sci. 2010, 11                       
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purple to deep blue [45]. Besides, their excellent biocompatibility makes Au-NPs able to be fashioned 
with a wide range of biomacromolecules such as nuclear acids and enzyme-linked antibodies, greatly 
extending their application in the colorimetric detection of tumor markers. Therefore, large numbers of 
Au-NPs based colorimetric immunoassays have been developed for the detection of tumor markers, 
oncogenes and even tumor cells [66–70].  
Apart  from  Au-NPs,  magnetic  particles  (MPs)  represent  another  exciting  prospect  in  current 
analytical fields because they can be easily separated from a matrix by using a magnetic field [71–73]. 
Taking advantage of their unique magnetic characteristic as well as excellent biocompatibility, MPs 
have been widely utilized as  a universal  separation tool in  the fabrication of colorimetric sensing 
systems for the detection of tumor markers [38,44,45,49,65,70]. 
2. Materials 
2.1. ELISA-Based Colorimetric Immunoassays 
2.1.1. Chemicals 
96-well microtiter plates and monoclonal/polyclonal capture antibodies are used for ELISA-based 
colorimetric immunoassays. 
Enzyme-labeled secondary antibody: hydrogen peroxidase (HRP)-labeled and alkaline phosphatase 
(ALP)-labeled  secondary  antibody  have  been  typically  used  in  ELISA-based  colorimetric 
immunoassays. 
Enzyme substrates: The commonly used substrate for HRP is hydrogen peroxide (H2O2), coupled 
with several hydrogen donors, such as 3,3’,5,5’-tetramethylbenzidine (TMB: Supplier: Acros Organics 
N.V.; Catalog No. 229280010), o-phenylenediamine dihydrochloride (OPD: Supplier: Acros Organics 
N.V.;  Catalog  No.  218480250)  and  2,2’-azino-di-[3-ethyl-benzothiazoline-6-sulfonic  acid] 
diammonium salt (ABTS: Supplier: Roche Applied Science; Catalog No. 10102946001). The most 
widely  used  ALP  substrate  is  p-nitrophenyl-phosphate  (pNPP:  Supplier:  New  England  BioLabs; 
Catalog No. P0757S). 
2.1.2. Buffer Reagents  
Carbonate/bicarbonate  coating  buffer:  100  mM  phosphate  buffered  saline  (PBS),  containing 
28.6 mM sodium carbonate (Na2CO3) and 71.4 mM sodium bicarbonate (NaHCO3), pH 9.6.  
Washing buffer: 10 mM PBS, pH 7.4, containing 150 mM sodium chloride (NaCl) and 0.05% 
Tween-20.  
Blocking buffer: PBS containing 0.1% bovine serum albumin (BSA) and 0.02% thimerosal.  
All buffer reagents and other inorganic chemicals can be supplied by Sigma, Aldrich, or Fluka. All 
chemicals are used as received, and all aqueous solutions are prepared with doubly distilled water. 
2.2. Nanomaterial-Based Colorimetric Immunoassays 
Monodispersed Au-NPs with size from 2 to 250 nm can be commercially received from Ted Pella 
Inc. (Catalog No. 15701-15714). Au-NPs can be also synthesized in laboratory. Materials needed for Int. J. Mol. Sci. 2010, 11                       
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the  synthesis  of  Au-NPs  are:  hydrogen  tetrachloroaurate  (III)  trihydrate  (HAuCl4· 3H2O,  99.9%. 
Supplier:  Acros  Organics  N.V.;  Catalog  No.  411070010),  trisodium  citrate  (Citrate· 3Na.  Supplier: 
Acros Organics N.V.; Catalog No. 391970025).  
MPs or functionalized MPs can be also commercially received. For example, amino-functionalized 
superparamagnetic microparticles (size 1–2 μm) can be obtained from Polysciences, Inc. (Catalog No. 
18879); streptavidin MagneSphere® paramagnetic particles (size 0.5–1.5μm) can be purchased from 
Promega Corporation. (Catalog No. MD1471).  
3. Methods 
3.1. ELISA-Based Colorimetric Immunoassays 
The most frequently used ELISA method in colorimetric immunoassays for tumor marker detection 
is the two antibody ―sandwich‖ ELISA, which measures the amount of antigen between two layers of 
antibodies [52]. In this assay, a capture antibody is firstly immobilized onto a solid support. The tumor 
marker, which is present in a biological sample or standard mixture, is then bounded and concentrated 
onto the support surface during incubation. After that, the solid support is incubated with a solution 
containing the detection antibody, thus the detection antibody will also bind with the tumor marker. 
Since the detection antibody is  also  tagged with  certain  enzymes, the color change caused by the 
enzyme-catalytic  reaction  can  be  thus  used  to  quantify  the  amount  of  target  tumor  marker.  The 
experimental details are described below, mainly with a slightly modified procedure recommended by 
Abcam [74]. 
3.1.1. Coating with Capture Antibody 
Coat the wells of a microtiter plate with the capture antibody at a concentration of 1–10 μg/mL in 
carbonate/bicarbonate coating buffer. Then cover the microtiter plate with an adhesive plastic. After 
incubation overnight at 4 ° C, remove the coating solution and wash the plate at least twice by filling 
the wells with 200 μL of washing buffer. The solution in the wells can be removed by flicking the plate 
over a sink, and the remaining drops in the wells can be removed by patting the plate on a paper towel. 
3.1.2. Blocking and Adding Samples 
200 μL of blocking buffer containing 5% non fat dry milk is firstly added into each well to block the 
remaining protein-binding sites. After that, the plate is covered with an adhesive plastic and incubated 
with the blocking buffer for at least 1–2 h at room temperature or overnight at 4 ° C. Then add 100 μL 
of appropriately diluted samples into each well, and incubate the plate with the sample solution for  
90 min at 37 ° C. After incubation, remove the samples and wash the plate twice by filling the wells 
with 200 μL of washing buffer.  Int. J. Mol. Sci. 2010, 11                       
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3.1.3. Incubation with Detection Antibody 
Dilute  the  detection  antibody  appropriately  with  0.1  M  bicarbonate buffer (pH 9.2). Then, add 
100 µL of the buffer solution to each well. Cover the plate with an adhesive plastic and incubate for 2 h 
at room temperature. After that, wash the plate four times with washing buffer. 
3.1.4. Colorimetric Detection 
Although many different types of enzymes have been used in ELISA, HRP and ALP are the two 
most widely used enzymes [43]. The substrate for HRP is H2O2, and the cleavage of H2O2 is usually 
coupled with the oxidation of a hydrogen donor which may change the color of the test solution during 
the reaction, so hydrogen donors should also be involved in the reaction. These hydrogen donors, 
usually TMB, OPD and ABTS, are light sensitive, so they need to be stored in the dark. Furthermore, 
OPD is considered hazardous (potential carcinogens), so it always needs to be handled with care. In a 
typical experiment, H2O2 and hydrogen donors are added into each well and incubated for 15–30 min. 
After that, equal volume of stopping solution (2 M H2SO4) is added to stop the reaction. Finally, the 
absorbance of the product of TMB oxidation is measured at the wavelength of 450 nm, while OPD at 
492 nm; ABTS at 416 nm. 
The most widely used ALP substrate is pNPP. The yellow color of the product nitrophenol can be 
measured at 405 nm after 15–30 min incubation at room temperature, and this reaction can be stopped 
by adding equal volume of 0.75 M NaOH.  
3.2. Nanomaterial-based Colorimetric Immunoassays 
The unique properties of nanomaterials may offer a wide range of opportunities in colorimetric 
immunoassays of tumor markers. In the following section, we provide experimental details for the 
synthesis,  surface  modification  and  utilization  of  nanomaterials  in  the  fabrication  of  colorimetric 
sensing systems for the detection of tumor markers. 
3.2.1. Synthesis and Modification of Nanomaterials 
3.2.1.1. Synthesis of 13 nm Au-NPs 
All glassware used in the synthesis procedures should be firstly immersed in freshly prepared aqua 
regia  (HNO3:  HCl  =  1:3)  for  30  min,  then washed with  water and dried before use. Au-NPs  are 
synthesized by reducing HAuCl4 with Citrate· 3Na. Briefly, a 100 mL aqueous solution of 0.01% (w/v) 
HAuCl4 is added into a round-bottom flask and stirred to boil. Then, 3.5 mL 1% trisodium citrate is 
added rapidly into the boiling solution, the color of which changes from colorless to wine red after 
boiling for another 15 min with vigorous stirring. The size of the nanoparticles is 12.5 ±  2.3 nm, which 
can  be  determined  by  transmission  electron  microscope  (TEM).  The  concentration  of  Au-NPs  is 
3.5 nM,  which  can  be  calculated  from  the  quantity  of  starting  material  (HAuCl4)  and  the  size  of  
Au-NPs at a wavelength of 520 nm [45]. Int. J. Mol. Sci. 2010, 11                       
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3.2.1.2. Modification of Au-NPs 
The main technique reported for the modification of Au-NPs surfaces is based on Au-S covalent 
bond formation between the modified molecules and the gold atoms on the particle surface [71], which 
makes use of sulphur-containing ligands, such as thiol, disulphide and thiolester.  
3.2.1.2.1. Modification of Au-NPs with Thiol-oligonucleotides 
The  above  prepared  Au-NPs  solution  is  firstly  condensed  by  centrifugation  at  12,000  rpm  for 
20 min at 4 °C  to a 1 mL Au-NPs solution, while 800 μL supernatant is removed; the remaining  
200 μL is redispersed. After condensation, 800 μL  Au-NPs solution is mixed with 200 μL, 5 μM 
5’-thiol-oligonucleotides  at  room  temperature.  After  24  h  duration  in  darkness,  the  mixture  is 
centrifuged twice, each for 20 min at 12,000 rpm to remove the excess thiol-oligonucleotides. After 
centrifugation,  the  precipitate  is  washed  with  4  mM  Citrate· 3Na.  The  Au-NPs,  modified  with  
thiol-oligonucleotides,  are  stored  at  4  ° C  when  not  in  use.  To  determine  the  number  of  
thiol-oligonucleotides  modified  on  each  Au-NP,  2-mercaptoethanol  (1.0  M,  10  μL),  which  has  a 
smaller size than oligonucleotides and is easier to be modified on the surface of Au-NPs through Au-S 
bond, is used to replace thiol-oligonucleotides from the surface of Au-NPs (11 nM, 990 μL). The 
amount of replaced thiol-oligonucleotides in the supernatant liquor can be thus used to calculate the 
quantity on each Au-NP [75]. 
3.2.1.2.2. Modification of Au-NPs with Antibodies 
The  methods  to  modify  Au-NPs  with  antibody  include  adsorption  [76],  N-hydroxysuccinimide 
(NHS) ester chemistry [77], and oligonucleotide-directed immobilization [78]. Among them, the direct 
adsorption method is the simplest one, due to the fact that neutral or weakly negative-charged proteins 
can be adsorbed on the surface of Au-NPs easily and stably through coordinate-covalent bond [79]. 
The preparation of Au-NPs modified with antibodies through direct adsorption is as follows [45]: 
20 μL of protein solution (1 mg/mL) is first added into 5 mL of the above prepared Au-NPs solution, 
and  the  pH  is  appropriately  adjusted  by  adding  1  M  NaOH  solution.  Then  the  mixed  solution  is 
incubated for 30 min at 37 ° C with gentle shaking, and centrifuged to 1 mL (12,000–13,000 rpm,  
20–30 min, 4 ° C). After that, 100 μL of 10% (w/v) BSA solution, used as non-specific blocker, is 
added into the solution to passivate the surface of Au-NPs. After 30 min, the mixed solution is again 
centrifuged (12,000–13,000 rpm, 20–30 min, 4 °C ). The supernatant is subsequently decanted, and the 
precipitate is rinsed with 1 mL of PBS buffer. The centrifuging/rinsing procedure should be repeated 
three times to remove the unbounded antibodies and BSA. 
3.2.1.3. Modification of MPs 
MPs may provide an efficient tool of separating target analytes from the liquid suspension; however, 
unmodified MPs have some limitations in the applications. Therefore, MPs surfaces should first of all 
be modified with some specific linking groups for further biomolecules binding, including: (1) Active 
chemical groups (e.g., carboxyl and amino groups), which can covalently bind biomolecules in the 
presence of specific cross-linking reagents; (2) streptavidin/avidin ligands, which can be specifically Int. J. Mol. Sci. 2010, 11                       
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attached  to  biotinylated  biomolecules  [71–73].  Taking  into  account  that  amino-  or  streptavidin-
functionalized MPs are commercially available, the following is only a description of the modification 
by antibodies for these pre-functionalized MPs. 
3.2.1.3.1. Modification of Amino-Functionalized MPs 
Amino-functionalized  MPs  can  be  modified  with  antibodies  by  using  glutaraldehyde-amine 
coupling  chemistry  [33].  Briefly,  amino-functionalized  MPs  (0.05  mM)  in  1  mg  mL
-1  of 
ethylenediaminetetraacetic acid (EDTA) solution (5 mL) are firstly washed with 5% (v/v) pyridine 
washing buffer (10 mL). Then, MPs are separated magnetically. This process should be repeated three 
times. After that, the MPs are activated by glutaraldehyde in pyridine washing buffer (5 mL, 5%) for  
3 h at room temperature, separated magnetically twice, and resuspended in pyridine washing buffer  
(10 mL). Finally, antibody dissolved in pyridine wash buffer (1 mL at 1 mg mL
-1) is added to the MPs 
solution. After 10 h duration at room temperature, 1 mg BSA is added to the MPs solution. After 
another 10 h at room temperature, the MPs are washed twice and then resuspended in pyridine washing 
buffer (5 mL). Subsequently, glycine solution (3 mL, 1 M at pH 8.0) is added into the above solution to 
quench all of the unreacted aldehyde groups, and the resulting solution is stirred for 30 min. After 
magnetic separation three times and the washing step, MPs modified with antibody (Ab-MPs) are 
resuspended in PBS solution. 
3.2.1.3.2. Modification of Streptavidin-Functionalized MPs 
Streptavidin-functionalized MPs are firstly washed three times with washing buffer (75 mM NaCl, 
7.5 mM Citrate· 3Na, pH 7.0) prior to use. Then they are diluted to 0.1 mg mL
-1 with PBS, pH 7.4. 
After that, a solution of biotinylated antibody is added to the MPs solution at a ratio of 100 μg protein 
to  1  mg  MPs,  and  the  mixed  solution  is  incubated  for  20  min  at  room  temperature.  Finally,  the  
Ab-MPs are thoroughly washed three times with pH 7.4 PBS [45]. 
3.2.2. Magnetic Collection and Separation of Target Tumor Markers 
MPs modified with capture antibodies can be used for fast target protein collection and separation. 
In a typical experiment, 50 µL of capture antibody-modified MPs (0.2 mg mL
−1) are first added to a 
200 µL eppendorf tube. Then, 50 µL of assay buffer containing various concentrations of target tumor 
markers are added. After incubation for 30 min at 37 ° C with gentle shaking, the magnetic beads are 
magnetically collected and twice rinsed with washing buffer [70]. 
3.2.3. Application of Au-NPs in Colorimetric Immunoassays of Tumor Markers 
Basically, two colorimetric procedures by making use of Au-NPs have been proposed for tumor 
marker  quantification:  (a)  Analysis  of  the  state  change  of  Au-NPs  in  solution,  including  the 
homogenous growth and aggregation triggered by a biological process; (b) analysis of the activity of 
enzymes that attached to Au-NPs, in which case Au-NPs act as enzyme carriers and signal enhancers.  
 Int. J. Mol. Sci. 2010, 11                       
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3.2.3.1. Colorimetric Assay Using Homogenous Growth of Au-NPs 
10 mL solution for the growth of Au-NPs is first prepared in a 20 mL vial, consisting of final 
effective concentrations of 0.25 mM HAuCl4 and 0.1 M cetyltrimethylammonium bromide (CTAB). 
Before  use,  the  solution  is  gently  mixed  with  ascorbic  acid  (AA)  solution  with  a  final  AA 
concentration of 10 mM and stirred. Seperately, Au-NPs/tumor marker complexes are first separated 
through magnetic separation and washed with 0.01 M PBS buffer (pH 7.4) three times to remove the 
excess of free Au-NPs. Then, Au-NPs are dissociated from the complexes by using 50 mM NaCl/1 M 
NaOH  elution  solution.  Finally,  the  upper  aqueous  solution  containing  the  dissociated  Au-NPs  is 
transferred to a 1 mL cuvette, followed by addition of the above previously prepared 1 ml solution for 
the  growth  of  Au-NPs.  The  growth  of  Au-NPs  and  the  color  change  of  the  solution  are  then  
recorded [38]. 
3.2.3.2. Colorimetric Assay Using Aggregation of Au-NPs 
In this section, we introduce the experimental details of two typical assays. One is based on single 
chain  fragment  variable  recombinant  antibody  (scFv)-functionalized  Au-NPs,  while  the  other  is 
colorimetric bio-barcode assay. 
3.2.3.2.1. scFv-Functionalized Au-NPs Based Assay 
Firstly, scFv-functionalized Au-NPs are prepared as described in Section 3.2.1.2.2. Then, a range of 
concentrations of target protein are added to the solution of the scFv-functionalized Au-NPs while 
stirring, thus the scFv-functionalized Au-NPs show visible color change due to the aggregation of the 
nanoparticles caused by the interaction of scFv with the target protein. After 30 min, the developing 
reaction can be recorded by using a UV-visible spectrophotometer [69].  
3.2.3.2.2. Colorimetric Bio-Barcode Assay 
In a typical experiment, two types of probes are prepared. The first is a magnetic probe, i.e., MP 
modified  with  monoclonal  antibodies  for  target  tumor  marker,  prepared  as  described  in  Section 
3.2.1.3.1. The second is a barcode probe, i.e., a porous silica particle modified with the monoclonal 
antibodies  and  barcode  DNA  complements.  To  prepare  the  barcode  probe,  amino-functionalized 
porous  silica  microparticles  are  firstly  linked  to  antibodies  using  glutaraldehyde-amine  coupling 
chemistry. Then, 3’-amino-functionalized barcode DNA complements (1 mL at 100 µM) are added to 
the  solution  containing  the  antibody  modified  silica  particles.  After  incubation  overnight  at  room 
temperature with gentle shaking, the solution is centrifuged twice, and the pellets are resuspended in 
1 mL of 0.2 M ethanolamine. After 30 min duration at room temperature, centrifugation is performed 
again to remove the supernatant, and a 10% BSA solution is subsequently added, followed by repeating 
the  centrifugation  steps  twice.  Finally,  the  resulting  pellets  are  resuspended  in  1  mL  of  
0.15 M PBS solution, which is further mixed with 30 µL 100 µM barcode DNA solution and incubated 
for 1 h at room temperature. 
In the tumor marker detection assay, 15 µL of magnetic probe solution (1.5 ×  10
9 beads/mL) is first 
added to 20 µL of tumor marker solution, followed by the addition of 15 µL of barcode probe solution Int. J. Mol. Sci. 2010, 11                       
 
 
5086 
(1 ×  10
9 beads/mL). The mixed solution is incubated at 37 ° C for 50 min on an orbital shaker. Then, 
the solution is magnetically separated as described in Section 3.2.2, and the magnetically separated 
complexes are washed with 0.15 M PBS solution three times. After that, 50 µL of NANOpure water 
(18 MΩ) is added to the complexes, and the solution is kept on a rocking shaker at 70 ° C for 10 min to 
release the barcode DNA. Finally, the supernatant containing free barcode DNA strands is collected for 
barcode  DNA  detection.  To  detect  the  barcode  DNA,  DNA-functionalized  Au-NPs  (prepared  as 
described in Section 3.2.1.2.1) are added to the barcode DNA in 0.15 M PBS solution. Due to the 
hybridization between the barcode DNA and its complements that are modified on Au-NPs surfaces, 
Au-NPs aggregate and show visible color change. And, the mixed solution, after being maintained at 
room temperature for 2 h, can be transferred into a 100-µL quartz cuvette to measure the extinction 
coefficients by using a UV-vis spectrophotometer [29,68]. 
3.2.3.3. Colorimetric Assay using Enzymes Labeled Au-NPs 
Due to the high loading of signaling molecules on each nanoparticle, greatly enhanced sensitivity for 
the  detection  of  tumor  markers  can  be  achieved  by  using  enzyme  labeled  Au-NPs  [70].  In  such 
colorimetric assays, Au-NPs play a role of enzyme carriers and signal amplifiers, and the detectable 
signals come from the catalytic reaction of the enzymes that are loaded onto the nanoparticle surfaces. 
The  commonly  used  enzymes  and  substrates  are  the  same  as  those  used  in  ELISA-based  
colorimetric assays.  
4. Results and Discussion 
As  an  example,  one  recent  work  in  the  authors’  laboratory  on  colorimetric  multiplexed 
immunoassays is introduced [45]. Figure 1 illustrates the principle of the assay for sequential detection 
of tumor markers. Briefly, biotin-anti-CEA conjugated MPs are first added to the test solution that 
contains CEA, AFP and some nonspecific proteins. After magnetic separation, CEA antigen which is 
captured  by  biotin-anti-CEA,  immobilized  on  the  surface  of  MPs,  is  thus  collected.  Therefore,  if  
Au-NPs loaded with HRP-anti-CEA are added to the collected CEA antigen solution, HRP-anti-CEA 
loaded on the surface of Au-NPs may capture the CEA antigen conjugated on the surface of MPs. 
Consequently, when TMB and H2O2 are added to the test solution, its color turns blue. Alternatively, 
the detection of AFP antigen in the test solution can be carried out by repeating the above procedure, 
using biotin-anti-AFP conjugated MPs and Au-NPs loaded with HRP-anti-AFP.  
The multiplexed immunoassay is very simple and easily operated, and the results can be seen by the 
naked eye (Figure 2). Meanwhile, the absorbance at 370 nm or 490 nm of the test solutions can be 
separately used to determine the amount of tumor markers more accurately. Under optical conditions, 
the  immunoassay  can  provide  sequential  detection  of  CEA  and  AFP  with  detection  limits  of 
0.02 ng/mL (≈0.1 pM), which can be satisfactory for clinical applications. Int. J. Mol. Sci. 2010, 11                       
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Figure 1. Scheme of the colorimetric multiplexed immunoassay for sequential detection of 
tumor markers, CEA and AFP. Reprinted with permission from Ref. [45]. Copyright 2009 
Elsevier. 
 
Figure  2.  Colorimetric  detection  of  CEA  and  AFP  antigens.  Only  in  the  presence  of 
antigens which are cognate with the antibodies loaded on the surfaces of MPs and Au-NPs, 
can the immunocomplexes be formed, and the characteristic blue and yellow colors of 
catalytic products be observed. Reprinted with permission from Ref. [45]. Copyright 2009 
Elsevier. 
 
Colorimetric assay is very simple and easily operated, without requiring the expensive instruments 
needed  in  the  optical  immunoassay  systems,  such  as  charge-coupled  device  (CCD)  camera  and  
multi-channel injection valves fixed to luminescence analyzers. In fact, electrochemical assay is also 
very simple and relatively inexpensive, thus some electrochemical methods have also been proposed Int. J. Mol. Sci. 2010, 11                       
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for the detection of cancer. However, the current amplification strategy for electrochemical signal often 
involves multiple steps of deposition and stripping, making the experimental process complex; while 
colorimetric approaches do not require complicated experimental steps, and results can be seen with 
the human naked eye. Therefore, colorimetric immunoassay for the detection of tumor markers has 
received more and more interest. Meanwhile, nanotechnology has greatly promoted the development of 
colorimetric immunoassays. Firstly, MPs may provide a rapid and safe approach to separate the target 
from  the  other  species,  preventing  the  interference  of  non-specific  proteins  in  immunoassays. 
Secondly, the unique optical properties of Au-NPs can be harnessed to realize the transduction of the 
presence  of  target  tumor  markers  to  easily  detectable  signals,  simplifying  the  designed  detection 
system.  Thirdly,  the  use  of  nanomaterials  has  enabled  detection  of  tumor  markers  with  greater 
sensitivity and accuracy. Therefore, colorimetric immunoassays have made prominent progress in the 
detection of tumor markers and may play an important role in the early diagnosis of cancer. 
Colorimetric immunoassays have many desirable merits, thus are rapidly developing. Tremendous 
opportunities  and  challenges  exist  in  the  application  of  colorimetric  methods  for  tumor  
marker detection.  
Firstly,  colorimetric  immunoassays  for  tumor  marker  detection  are  usually  proposed  by  using 
antibodies; however the availability of antibodies with high affinity and low cross-reactivity are very 
limited.  Fortunately,  aptamers—nucleic  acid  molecules  that  can  selectively  bind  to  low  molecular 
weight organic or inorganic substrates or to macromolecules such as proteins—can be considered as 
attractive alternatives  to  antibodies [45].  In fact, compared with antibodies, aptamers may possess 
many advantages, such as relatively simple and inexpensive synthesis, tolerance to internal labeling, 
high stability, and stronger and more selective affinity for protein targets. Therefore, several aptamers 
have been employed for tumor marker detection [80,81].  
Secondly, nanomaterials used in colorimetric methods for sensing tumor markers are still narrowly 
restricted to Au-NPs and MPs. Recently, some novel types of nanomaterials were fabricated and used 
in colorimetric biosensors for various analytes [82–84], so more nanomaterials will be applied in the 
development  of  colorimetric  immunoassays  for  tumor  marker  detection,  simplifying  the  assay 
methodology and lowering the detection limit as far as possible. 
Finally, the measurement of a single tumor marker is usually not sufficient for diagnosis purposes, 
because  most  cancers  have  more  than  one  marker  associated  with  their  incidence  [85],  thus 
multiplexed  immunoassays  that  can  quantitatively  measure  the  concentrations  of  multiple  tumor 
markers in a single assay have received more and more interest [25,46]. Compared with the traditional 
parallel  single-analyte  immunoassay,  multiplexed  immunoassays  have  the  advantage  of  simplified 
analytical  procedure,  shortened  analysis  time,  decreased  sample  consumption,  increased  test 
throughput, reduced costs, and improved diagnostic accuracy [45]. Consequently, future advances in 
colorimetric  immunoassays  will  depend  on  the  development  of  simple  and  efficient  sensing 
mechanisms for multiplexed tumor marker examinations. 
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